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ABSTRACT
Objectives: This study evaluated the uptake of
Western Australian (WA) pharmacist vaccination
services, the profiles of consumers being vaccinated
and the facilitators and challenges experienced by
pharmacy staff in the preparation, implementation and
delivery of services.
Design: Mixed-methods methodology with both
quantitative and qualitative data through surveys,
pharmacy computer records and immuniser pharmacist
interviews.
Setting: Community pharmacies in WA that provided
pharmacist vaccination services between March and
October 2015.
Participants: Immuniser pharmacists from 86
pharmacies completed baseline surveys and 78
completed exit surveys; computer records from 57
pharmacies; 25 immuniser pharmacists were
interviewed.
Main outcome measures: Pharmacy and immuniser
pharmacist profiles; pharmacist vaccination services
provided and consumer profiles who accessed
services.
Results: 15 621 influenza vaccinations were
administered by immuniser pharmacists at 76 WA
community pharmacies between March and October
2015. There were no major adverse events, and <1%
of consumers experienced minor events which were
appropriately managed. Between 12% and 17% of
consumers were eligible to receive free influenza
vaccinations under the National Immunisation Program
but chose to have it at a pharmacy. A high percentage
of vaccinations was delivered in rural and regional
areas indicating that provision of pharmacist
vaccination services facilitated access for rural and
remote consumers. Immuniser pharmacists reported
feeling confident in providing vaccination services and
were of the opinion that services should be expanded
to other vaccinations. Pharmacists also reported
significant professional satisfaction in providing the
service. All participating pharmacies intended to
continue providing influenza vaccinations in 2016.
Conclusions: This initial evaluation of WA pharmacist
vaccination services showed that vaccine delivery was
safe. Convenience and accessibility were important
aspects in usage of services. There is scope to expand
pharmacist vaccination services to other vaccines and
younger children; however, government funding to
pharmacists needs to be considered.
BACKGROUND
Immunisation is one of the most significant
public health interventions of the past
200 years, preventing the spread of many dis-
eases that result in serious ongoing health
outcomes, hospitalisations and sometimes
death.1 It has been estimated that vaccines
prevent more than 2.5 million deaths annu-
ally.2 The underusage of immunisation pro-
grammes, however, continues to be a
significant public health concern.3 4 Factors
that contribute to low immunisation rates
have been reported in various studies5–7 and
include misconceptions, inconvenience, cost
and general public apathy.8
Community pharmacists are accessible
healthcare professionals who provide health
advice and expertise across a wide range of
health-related areas.9 Adding pharmacists to
the list of health professionals who may
administer vaccines has the potential to
increase vaccine uptake. Pharmacists have
been providing vaccination services over the
last decade in countries such as the USA,10
Strengths and limitations of this study
▪ This is the first study that comprehensively eval-
uated the implementation of pharmacist immun-
isation services in Australia and the uptake of the
services.
▪ Mixed methodology was employed to obtain
quantitative and qualitative data through surveys,
pharmacy computer records and interviews.
▪ The various data sources enabled contextualising
and triangulation of information and hence
enriched the exploration of the research topic.
▪ Voluntary self-administered baseline and exit
surveys to pharmacists who chose to provide
pharmacist immunisation services and interviews
with immuniser pharmacists could have caused
participant bias.
▪ This study was conducted in Western Australia
and findings might differ in other Australian jur-
isdictions due to slight differences in legislative
provisions.
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the UK,11 Canada,4 Portugal12 and New Zealand (NZ).13
The easy access to community pharmacists is one of the
major benefits of pharmacist immunisations and these
programmes have been shown to lead to increased vac-
cination rates, low adverse effects and high consumer
satisfaction.9 14–21
In the USA, the types of immunisations and the age
groups to which they can be delivered vary between
states and include seasonal influenza and travel vaccines,
human papilloma virus (HPV), hepatitis A and B, men-
ingococcal and pneumococcal vaccines. In some states,
certain vaccines can be administered by pharmacists to
children as young as 6 years of age.15 Pharmacists in
Canada have been administering seasonal influenza vac-
cinations for people 5 years and over since 2012.17 18
Similar programmes have been trialled through some
community pharmacies for several years in the UK for
seasonal influenza while others include travel vaccina-
tions and HPV.20–22 In 2015, a national England-wide
programme was introduced for community pharmacy
influenza vaccinations.23 In NZ, pharmacists have been
able to vaccinate consumers over 18 years of age since
2011.24 Apart from influenza vaccinations, suitably quali-
fied pharmacists are able to administer the combined
diphtheria, tetanus and acellular pertussis vaccine, men-
ingococcal and zoster vaccines to adults with expecta-
tions of expansions in the near future.24
In December 2013 the Pharmacy Board of Australia
(PBA) announced that vaccination was within the scope
of practice of pharmacists.25 The Australian Pharmacy
Council subsequently developed training accreditation
standards26 and professional organisations developed
practice guidelines.27 28 As the administration of medi-
cines, including vaccinations, is regulated under jurisdic-
tional medicines and poisons legislation29 individual
jurisdictions had to amend legislation to allow pharma-
cists to administer vaccines.30 In early 2014, the
Queensland Pharmacist Immunisation Pilot (QPIP) was
introduced and resulted in 11 475 adults (individuals
aged 18 years and over) being vaccinated against influ-
enza. More than 8000 consumers completed a postvacci-
nation survey showing 93% satisfaction with the
service.31 The pilot was broadened to the Northern
Territory in July 2014 and expanded to vaccinations for
measles and whooping cough.32
In December 2014, Western Australia (WA) was the
first state to make legislative changes allowing state-based
implementation of pharmacists to administer influenza
vaccines to adults (defined as over the age of 18 in WA)
without a prescription, in a pharmacy, under the WA
Pharmacist Vaccination Code.33 34 The Code specifies
that WA pharmacists should refer individuals who qualify
for the National Immunisation Program (NIP) to partici-
pating NIP service providers such as a medical practi-
tioner. In other words, there has been no specific
government funding arrangement in WA and individuals
who decide to receive pharmacist-administered influenza
vaccinations have to pay at a price determined by the
individual pharmacies or be reimbursed by their private
health insurance providers. In Australia, those who
qualify to receive free influenza vaccinations under the
NIP include:35
▸ Individuals aged 65 years and over;
▸ Aboriginal and Torres Strait individuals aged
6 months to <5 years;
▸ Aboriginal and Torres Strait individuals aged 15 years
and over;
▸ Pregnant women;
▸ Individuals aged 6 months and over with chronic
medical conditions which can lead to influenza com-
plications, for example, severe asthma, low immunity,
heart or lung disease or diabetes.
Other jurisdictions namely South Australia, New South
Wales, Tasmania and the Australian Capital Territory sub-
sequently introduced similar legislative changes.36 In May
2016, the Victorian Government announced its approval
of pharmacist-delivered vaccinations, enabling pharmacists
in Victoria to administer influenza and pertussis-
containing vaccinations to adults (over the age of 17) on
successful completion of relevant training. This includes
vaccinations provided to individuals who qualify for free
vaccinations under the NIP and the Victorian Government
Parent’s Whooping Cough Vaccination programme.37
The structured evaluation of WA pharmacist vaccin-
ation services from pharmacists’ perspectives as well as
the potential public health impact was vital to assess the
initial implementation and sustainability of this new ini-
tiative. This paper reports on the evaluation of pharma-
cist vaccination services provided in 2015.
Objectives:
1. Explore the uptake of pharmacist-administered vac-
cination services;
2. Evaluate the profiles of consumers who received
pharmacist-administered influenza vaccinations in
2015;
3. Evaluate the facilitators and challenges experienced
by pharmacy staff in the preparation, implementation
and delivery of services.
METHODS
Mixed methodology was employed involving quantitative
as well as qualitative approaches to obtain data from a
number of sources:
1. Pharmacy baseline survey completed by pharmacy staff
at the initiation of the project to gather information
about pharmacy profiles;
2. End-of-project pharmacy exit survey completed by phar-
macy staff to obtain information about services pro-
vided, adverse events, facilitators and challenges;
3. Audit of pharmacy vaccination service records to
evaluate services provided and consumer profiles;
4. Exit interviews with immuniser pharmacists to explore
immuniser pharmacists’ perspectives on their train-
ing, services provided, adverse events and broader
impacts.
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Surveys and the exit interview tool were developed
considering the literature and were validated by the
Project Evaluation Team, four pharmacy academics and
two independent pharmacists, and were subsequently
amended to incorporate suggestions.
Recruitment
A total of 309 WA pharmacists successfully completed
pharmacist immunisation training between March and
June 2015, and were employed at 158 WA community
pharmacies. Of the pharmacies, 133 offered pharmacist
vaccination services in 2015 and were eligible to partici-
pate in the study. Purposive sampling was used to invite
these pharmacies to participate. The pharmacies
received a study information sheet and pharmacy
owner/manager and pharmacist consent forms during
visits by representatives of pharmacy professional organi-
sations. The representatives provided assistance with the
implementation of pharmacist vaccination services.
Pharmacy baseline survey
Surveys were subsequently sent by mail to participating
pharmacies in April 2015 to collect data about the
profile of the pharmacy, previous and intended provi-
sion of vaccination services, staff profiles including
details about the immuniser pharmacist(s), reasons for
providing vaccination services, how appointments would
be managed and price to be charged. Follow-up emails
and phone calls were made to increase response rates.
Pharmacy exit survey
During August 2015, participating pharmacies were
invited to complete another survey to collect information
about the vaccination services provided, whether there
were any consumers who experienced an adverse event
(mild local reaction, mild systemic reaction, severe reac-
tion, epinephrine required), the impact of the service on
professional relationships (ie, with general practices) and
planned provision of future vaccination services. Surveys
were mailed to the pharmacies and follow-up emails and
phone calls made to increase response rates.
Pharmacy computer records
Data from some participating pharmacy computer records
were collected and compiled mid-October 2015, several
weeks after the end of the influenza season. De-identified
data from consumers who received pharmacist vaccination
services provided information about service dates (peaks
and troughs), the number of consumers who received ser-
vices and consumers’ demographics.
Pharmacist exit interviews
Immuniser pharmacists were invited to participate in a
semistructured telephone interview to explore opinions
about immunisation training, implementation of the
service, experiences with consumers including the man-
agement of adverse effects, facilitators and challenges
experienced in the implementation of the service and
the impact of the service.
Immuniser pharmacists who agreed to be interviewed
were categorised based on the number of vaccinations
delivered, the type of pharmacy where the vaccination
service was delivered and the Pharmacy Access/
Remoteness Index of Australia (PhARIA)38 category. Of
the 44 pharmacists that agreed to be interviewed, 25 were
chosen as this number was estimated to be sufficient to
reach thematic saturation.39 40 Interviewees were selected
according to the range, type of pharmacy and PhARIA
category to reflect a representative sample. Interviews
were conducted in October 2015. Each participant
received a $50 gift card as a token of appreciation.
Data analysis
Simple descriptive statistics (frequencies and percentages
for categorical variables, medians and ranges for variables
measured on a continuous scale) were used to summarise
the baseline and exit survey responses. Similar descriptive
statistics were used to summarise the pharmacy computer
records or vaccinations provided. A Poisson regression
model was used to explore any factors associated with the
proportion of pharmacists employed at each pharmacy
who were immunisers. The dependent variable for this
model was the number of immuniser pharmacists, with
the total number of pharmacists at the pharmacy identi-
fied as the ‘offset’ variable. The results are expressed as
rate ratios, their 95% CIs and p values. A general linear
model was used to explore factors associated with the
number of vaccinations performed. As this dependent
variable was skewed, analysis was performed on its loga-
rithm. In the results, means are quoted on the original
scale (for ease of interpretation) and the p values are
quoted from analysis of the log-transformed data. The
Statistical Package for the Social Sciences (SPSS; IBM
Corporation. IBM SPSS Statistics for Windows, Version
22.0. Armonk, New York: IBM Corp, Released 2013) V.22
software was used for quantitative data analysis, and a
p value <0.05 was taken to indicate a statistically signifi-
cant association in all tests.
Interviews were audio-recorded, then de-identified and
transcribed verbatim. NVivo V.10 was used to organise
qualitative data and thematic analysis of the data were
informed by the general inductive approach.41 The tran-
scripts were read repeatedly to gain an in-depth under-
standing of the topics that had emerged from the
interviews. Initial codes or ‘ideas’ were generated and then
grouped into categories to form the subthemes. These sub-
themes were then rearranged to form the six main themes.
RESULTS
Pharmacy baseline and exit surveys as well as pharmacy
computer records provided quantitative data. Qualitative
results reflected immuniser pharmacist interviews.
Pharmacy baseline survey
Of the 133 pharmacies that provided pharmacist vaccin-
ation services in 2015, 86 (64.7%) pharmacy owners/
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managers agreed to take part in the study and returned
baseline surveys.
Table 1 summarises the profiles of the participating
pharmacies. The majority of pharmacies were in neigh-
bourhood shopping centres (36.0%) or city/suburb/
town centre locations (24.4%). The overall percentage
of pharmacists working at each pharmacy who were
trained immunisers varied from 20% to 100%. The pro-
portion of pharmacists who were immunisers varied
from 45% in city/suburb/town locations to 58% in stan-
dalone pharmacies, and 70% in regional pharmacies.
However, these proportions were found not to be statis-
tically significantly different using the Poisson regression
model (p=0.118). When comparing the proportions
between urban (47%) and regional pharmacies, the
higher proportion in the regional areas did appear to
be marginally statistically significant (rate ratio 1.5; 95%
CI 1.0 to 2.2; p=0.048).The majority of pharmacies
(73%) typically had at least two pharmacists in the phar-
macy at any specific time. The number of vaccinations
performed during 2015 in pharmacies where only one
pharmacist was generally working was lower than others
(raw means 129 vs 224; mean difference on log scale
0.65; 95% CI 0.00 to 1.29; p=0.049). While the differ-
ence on the original scale appears large (partly due to
skewness), the analysis of the log-transformed data
showed the difference was of borderline statistical signifi-
cance. In this situation, the pharmacist may have insuffi-
cient time to provide vaccinations and deal with other
job demands. However, pharmacies with only one
pharmacist on duty are also more likely to be smaller
pharmacies dealing with a smaller number of customers,
so no particular conclusion can be drawn on this
association.
A large number of pharmacies had 1 (45.3%) or 2
immuniser pharmacists (33.7%). There were a total of
346 pharmacists (123 owners/managers, 223 other
employed pharmacists) at the 86 pharmacies with 272
(78.6%) having current first aid certificates (98 owners/
managers, 174 other pharmacists). Most pharmacies
(90.7%) already had consultation areas and the majority
of these areas were suitable for vaccination services
(89.7%). Overall 93.0% provided MedsCheck
(in-pharmacy medication review) services and 90.7%
provided Diabetes MedsCheck services. Forty-two of the
86 pharmacies (48.8%) provided vaccination services in
the previous 12 months, delivered by another healthcare
professional (nurse or nurse practitioner). These health
professionals provided ∼4023 vaccinations (2–400 per
pharmacy) over the previous 12-month period.
Table 1 Pharmacy categories, profiles and 2015 vaccination services provided
Variable (categorical variables) N (%)
Location of pharmacy
Neighbourhood shopping centre 31 (36.1)
City/suburb/town centre 21 (24.4)
Regional shopping centre 13 (15.1)
Standalone 12 (14.0)
Medical centre/other 9 (10.5)
Pharmacies with a consulting area 78 (90.7)
Pharmacies with an area suitable for immunisations 70/78 (89.7)
Number of Immuniser pharmacists
1 39 (45.5)
2 29 (33.7)
3 or more 18 (20.9)
Immunisations previously performed by other healthcare professionals 42 (48.8)
Nurse practitioner 31/42 (73.8)
Registered nurse 11/42 (26.2)
Services currently offered
MedsCheck 80 (93.0)
Diabetes MedsCheck 78 (90.7)
Variable (number per pharmacy) Median (range); mean (SD)
Pharmacists (owner/manager+employed pharmacists) 4 (2–10); 4.1 (1.7)
Immuniser pharmacists 2 (1–6); 1.9 (1.0)
Pharmacists working at any particular time 2 (1–4); 2.0 (0.8)
Proportion of all pharmacists who are immunisers 0.4 (0.2–1.0); 0.5 (0.3)
Pharmacists with first aid certificate 2 (0–8); 2.1 (1.4)
Support staff with first aid certificate 0 (0–25); 1.3 (3.1)
Number of vaccinations provided during 2014 51 (2–400); 98.1 (90.4)
Number of vaccinations provided during 2015 101.5 (0–1252); 200.3 (260.1)
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Table 2 Reasons for providing pharmacist vaccination services and planned future services
Baseline survey
Main reasons for the pharmacy offering pharmacist vaccination services
Strongly
agree (%) Agree (%)
Neither agree nor
disagree (%) Disagree (%)
Strongly
disagree (%)
To increase consumer immunisation rates 61/85 (71.8) 21/85 (24.7) 3/85 (3.5) 0 0
To provide health promotion opportunities 59/86 (68.6) 27/86 (31.4) 0 0 0
To enhance the role of pharmacists 72/86 (83.7) 14/86 (16.3) 0 0 0
For financial gains 26/86 (30.2) 31/86 (36.0) 24/86 (27.9) 4/86 (4.7) 1/86 (1.2)
To provide holistic patient care opportunities (health hub) 45/86 (52.3) 33/86 (38.4) 8/86 (9.3) 0 0
For professional satisfaction of pharmacists 51/86 (59.3) 26/86 (30.2) 9/86 (10.5) 0 0
How pharmacists intend to provide vaccination services in terms of pharmacist time management
All of the time (%) Most of the time (%) Unsure (%) Some of the time (%) Not at all (%)
Appointment system during all pharmacy trading hours 5/77 (6.5) 16/77 (20.8) 7/77 (9.1) 17/77 (22.1) 32/77 (41.6)
Appointment system during specific pharmacy trading hours 28/83 (33.7) 32/83 (38.6) 3/83 (3.6) 11/83 (13.3) 9/83 (10.8)
Walk-in therefore no appointment necessary 13/86 (15.1) 36/86 (41.9) 3/86 (3.5) 28/86 (32.6) 6/86 (7.0)
Exit survey
Planned future vaccination services in 2016
Strongly agree (%) Agree (%)
Neither agree nor
disagree (%) Disagree (%)
Strongly
disagree (%)
Intend to continue providing influenza vaccinations in 2016 73/78 (93.6) 4/78 (5.1) 1/78 (1.3) 0 0
Wish to expand the service to other vaccinations 66/78 (84.6) 10/78 (12.8) 2/78 (2.6) 0 0































Using a five-point Likert scale, 72.1% either agreed or
strongly agreed that their relationship with local general
practices extended beyond sorting out dispensing issues.
However, only 29.1% indicated that they regularly met to
discuss patient care issues.
The main reasons for providing pharmacist vaccin-
ation services were identified using a five-point
Likert-scale (table 2). All pharmacies either strongly
agreed or agreed that it was to provide health promotion
opportunities and to enhance the role of pharmacists,
96.5% indicated that it was to increase consumer
immunisation rates, 90.7% that it was to provide holistic
patient care opportunities and 89.5% for professional
satisfaction of pharmacists. The lowest score was 66.3%
which was for financial gain. Many participants (72.3%)
indicated that they would either all of the time or most of
the time offer the service through an appointment system
during specific pharmacy trading hours, 57.0% indicated
that they would manage through walk-in without appoint-
ments and only 27.3% would use an appointment system
during all pharmacy trading hours.
Pharmacy exit survey
Of the 86 pharmacies that completed baseline surveys,
78 (90.7%) completed exit surveys. A total number of
15 621 influenza vaccinations were provided during the
2015 influenza season by 76 of the pharmacies (2 phar-
macies did not provide services). Of these, 1855 (11.9%)
were delivered to consumers who were eligible to receive
influenza vaccinations under the NIP but chose to have
it at the pharmacy. A total of 379 consumers (2.4%)
were deemed not suitable for pharmacist vaccinations
and were referred to a medical practitioner. Overall, 119
(0.76%) consumers experienced a mild local reaction
and 19 (0.12%) experienced a mild systemic reaction
(eg, headache) within 15 min postvaccination. None of
the consumers experienced a severe reaction and none
required the use of epinephrine.
Almost all of the pharmacist participants (98.7%;
n=77/78) either strongly agreed or agreed that they
intended to continue providing influenza vaccinations in
2016 and 97.4% (n=76/78) indicated it appropriate to
expand the service to other vaccinations (table 2).
Overall, 32.1% (n=25/78) of participants strongly agreed
or agreed that it improved relationships with other local
area health professionals and 26.9% (n=21/78) either
strongly agreed or agreed that they experienced support
from the local general practices.
Regional shopping centre pharmacies, on average,
provided the highest number of vaccinations compared
with other pharmacy types (table 1). This may be
related to the higher proportion of immuniser pharma-
cists available in the regional areas.
Pharmacy computer records
Of the participating pharmacies, 57 used a software
program called GuildCare42 to record the vaccination ser-
vices provided. The other pharmacies used paper-based
systems or alternative software and their computer
records were not available for analysis. The GuildCare
data were extracted from the GuildLink Tableau
platform.
The 57 pharmacies provided a total of 5588 pharma-
cist vaccination services during January to September
2015. The peak period was mid-25 April with a second
peak during 3–9 May 2015. In terms of time of day
when the vaccination services were provided, 11:00–
12:00 was the most popular followed by 10:00–11:00.
Overall, most of the services were provided during after-
noons. A total of 264 services were provided between
18:00 and 23:00. The majority of consumers were
50 years and older (56.8%; n=2914/5126) with 50.6%
between 50 and 65 years old. A total of 932 consumers
(16.7%) were identified as qualifying under the NIP.
Most of them (91.0%; n=848/932) were aged 65 years
and over and some (7.1%; n=66/932) had a chronic
illness, were pregnant (1.4%; n=13/932) or were classi-
fied as Aboriginal and Torres Strait Islanders (ATSIs;
0.5%; n=5/932).
A cross-match of pharmacy postcodes with the post-
codes of consumers that were vaccinated showed that the
majority of patients lived in the postcode where the phar-
macy was located. Pharmacist vaccination services were
spread over a wide geographical area. Of specific interest
was the high percentages of vaccinations delivered in a
regional (Kalgoorlie, PhARIA category 3) and rural area
(Esperance, PhARIA category 5; 23.1%; n=1010/4376).
Pharmacist exit interviews
Of the 25 pharmacists who were interviewed, 10 were
males and 15 were females. Saturation of data occurred
after ∼15 interviews; however, the process continued to
ensure representation from a range of pharmacies.
The median number of vaccinations given per pharmacy
was 84 (range 5–1252, total vaccinations by 25 partici-
pants=5391). Service charges (inclusive of vaccine) ranged
between $19.95 and $30.00 for the trivalent vaccines and
between $30.00 and $39.95 for the quadrivalent vaccines.
Charges for some consumers were partially or fully subsi-
dised by a private health insurance company. The demand
for vaccination services was reported to exceed pharma-
cists’ expectations:
We had quite a very big demand on it. People, as soon as
they heard about, [that] they could do it in the phar-
macy, no appointment, no script required—we had a
great response from consumers. (P139)
Adverse events reported by the pharmacists included
mild local injection site reactions, light headedness,
fainting and slight fever several days postvaccination. In
all of these cases, pharmacists appeared to be well
informed of the possible adverse effects of the vaccine,
and protocols were in place and followed when man-
aging these situations, which included appropriate con-
sumer follow-up.
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Six main themes emerged through the thematic analysis





▸ Community pharmacists’ role,
▸ Positive service impact.
Facilitators and challenges
Table 3 provides selected quotations related to facilita-
tors and challenges. Convenience and accessibility of
community pharmacies were identified as major factors
facilitating the demand and uptake of vaccination ser-
vices by consumers. Pharmacists believed that offering
the service via both appointment-booking and walk-in
(no waiting time) systems provided convenience and
flexibility to the consumers and encouraged uptake of
the service. It was also reported that some consumers
who would qualify under the NIP for free vaccinations
were willing to pay for the vaccination service in the
pharmacy due to convenience. Participants who did not
qualify under the NIP mentioned that being vaccinated
at the pharmacy was preferential to be vaccinated at
their general practitioner (GP) because, as consumers,
they saved time and GP fees. Credibility of pharmacists
and pharmacist–client relationships were identified as
important facilitators as some pharmacists had long-
standing relationships with consumers.
Challenges experienced included workforce issues, fear
of jeopardising relationships with GPs, competitive pricing,
unavailability of stock, pharmacy physical layout issues,
training fees and promotion of the service to consumers.
Pharmacists’ needs
Several needs were identified as participants described what
was considered necessary to ensure efficiency and improve-
ment of pharmacist vaccination services. These included a
government funding model or government subsidy of
pharmacist vaccination services (such as adding pharmacists
as NIP providers with remuneration for service provision)
and entry and access to the National Vaccination Register.
Participants also expressed a need for the re-evaluation of
the requirement for two pharmacists to be at the pharmacy,
specifically in rural areas. Support from manufacturers and
professional organisations were also highlighted.
Pharmacists’ confidence
Overall, the immuniser pharmacists were confident in
providing vaccination services. Positive feedback from
consumers, practice and experience in administering
vaccines, and the presence of procedures and guidelines
were identified as three major factors that affected confi-
dence levels (figure 2 with selected quotations).
Community pharmacists’ role
Pharmacists were perceived as convenient, easily access-
ible and credible health professionals who are well
Figure 1 Schematic representations of the relationships between interview themes. GP, general practitioner; NIP, National
Immunisation Program.
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Table 3 Facilitators and challenges to provision of pharmacist vaccination services
Facilitators Supporting quotations
Convenience and accessibility “…a lot of customers found it very convenient to just walk in to the pharmacy
and be able to get the immunization done in maybe 15, 20 minutes without
going to a doctor.” (P127)“I’ve found that people use the service because it
was convenient. Even if they could receive a free one—which I always told
them about—for convenience and ease of access, they often chose to pay for
the service rather than going to their doctor, just because we’re open after
hours and it seemed very convenient for people. I get a lot of good feedback
from people too.” (P89)
Pharmacist credibility “…they’re very comfortable to come to me rather than just going to any doctor
that might be here, considering that I’ve been in this town 16 years as their
pharmacist…it was a great professional service that we could add to our
pharmacy, and [they] were more than happy for me to do it, knowing the
rapport I have with my community members, my customers.” (P29)
Overall cost-benefit “…especially those patients who don’t qualify for…under the National
Immunisation Program. It’s much cheaper than seeing a doctor [who] doesn’t
bulk bill, to come into the pharmacy and have it administered.” (P38)
Challenges Supporting quotations
Staffing issues (pharmacists and
assistants), especially in rural areas
“…extreme difficulty for covering pharmacy. It won’t happen in the rural areas
anymore because it’s very hard to find a pharmacist-- to find a pharmacy
where you’ve got two pharmacists anymore.” (P29)“Some actually were
disappointed that sometimes the service couldn’t be offered sooner, only
because I’m a sole pharmacist and we only ever conducted the clinics when
we had two pharmacists on duty.” (P70)
Competitive pricing on service charges “…XXX are doing it at very cheap prices because they [have] the nurse. In
terms of pharmacy, it’s very hard to compete whereby the nurses get subsidy
from the government. Because the pharmacy doesn’t get a subsidy from the
government, the prices are generally higher.” (P75)“I think a lot of consumers
were wondering why we would charge $24 when they could go to XXX or
something and get it for $9.99, but not realising that it was being administered
by doctor and more fees were involved through a Medicare system.”(P87)
Fear of jeopardising relationship with GP “…because we’re in the medical centre, having the doctors next door, it’s one
of those things whereby you don’t want to obviously tread on their
toes…”(P75)“Our local medical centre told us not to bother sending those
information sheets saying that we had injected people, they just said, “No, we
don’t want to know about it.” so that wasn’t too good.”(P85)
Availability of stock “…getting the vaccine was a little bit troublesome only because obviously
there was no stock available at the very beginning.”(P70)
Time constraints “…the demand initially, especially in the first month, was great and I think we
possibly could have put more staff into…we could have had a little bit longer
clinic hours and possibly looked at having more staff but that’s difficult to
anticipate…”(P49)“…the time involved in coordinating everything…” (P53)
Logistical issues in meeting the
requirements
“One of the biggest things is trying to get the pharmacy to meet the
requirements for vaccination. That was one of the big things because our
pharmacy is not big so having to try and get the diameters and meet that
[requirement].”(P75)
Course fees in getting pharmacists qualified “I think the barrier is the cost of the course as well. I think it potentially saves
Medicare a fortune in consults to the doctor, and perhaps the government
could assist in getting more people trained. Perhaps the course could be
streamlined to make it cheaper.”(P38)
Lack of publicity “I think more consumers should be aware that they can get it in the
pharmacy…” (P150)
Communication with consumers “Our demographics is…we a few people who don’t speak English very well, so
we had a few people who said, ‘I’m sorry, I can’t fill out particularly because I
can’t speak and I don’t understand’.” (P134)
GP, general practitioner.
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placed to provide vaccination services. Pharmacists were
also perceived as an alternative vaccination service pro-
vider to GPs, especially for those consumers not covered
the NIP. The willingness of pharmacists in becoming
immunisers and their support of service expansion were
apparent, as described by one participant: “We’re just
hoping it can be expanded and continued in the future”
(P29). Despite being an advocate for professional
service expansion, participants of this study appeared to
be aware of their strengths and limitations, and were
conversant with the relevant guidelines and regulations.
All 25 participants agreed that pharmacist vaccination
services should be expanded to other vaccinations. In
addition to influenza vaccination, other vaccinations sug-
gested included pertussis, tetanus, measles, mumps and
rubella, hepatitis A and B, pneumococcal, typhoid and
travel vaccines.
Positive service impact
The impact of vaccination services on the professional
image of pharmacy was paramount and extended
beyond the context of immunisation services. In add-
ition to promoting the professional image of pharmacies
and pharmacists, it was evident that the provision of vac-
cination services encouraged the uptake of other profes-
sional services in the pharmacy:
…they see a pharmacy more as a health provider and it
gives that extra boost of health providing rather than just
drugs and medication…it gives pharmacy a bigger scope
of practice in terms of health care and health manage-
ment…talk to them about the other services that a phar-
macy provides…they were all quite shocked [surprised]
that pharmacies do blood pressure readings and stuff like
that. I think it is an opportunity to talk about their
health matters with the patients…(P75)
In the context of convenience and accessibility, it was
identified that by offering the service through commu-
nity pharmacies, pharmacists could contribute towards
increasing the immunisation rates especially among
those not covered under the NIP: “They’re usually the
Figure 2 Factors affecting
pharmacists’ confidence levels.
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ones that don’t hold the appointments with the doctors,
that aren’t going to go to the doctors, and really are
often quite time poor” (P18). Increasing the vaccination
rates may also lead to other positive impacts, such as
herd immunity and public health promotion: “…it just
helps to protect the community in terms of herd
immunity and so forth” (P48).
Participants stated that pharmacist vaccination services
could help reduce the burden on the Australian health
system and reduce GPs waiting times: “you’re reducing
doctors’ time; you’re reducing probably the expense and
the workload on to the PBS [Pharmaceutical Benefits
Scheme]…” (P85). Furthermore, referral of consumers
covered under the NIP to GPs encourages communica-
tion between pharmacists and GPs, which enhances
pharmacist–GP relationships and promotes interprofes-
sional collaboration.
DISCUSSION
In total, 15 621 influenza vaccinations were administered
at 78 WA community pharmacies by immuniser pharma-
cists between March and October 2015. There were no
major adverse events, and <1% of consumers experi-
enced minor events which were appropriately managed
within the pharmacies. Between 12% and 17% of consu-
mers were eligible to receive free influenza vaccinations
under the NIP but chose to have it at a pharmacy. Of
specific interest was the high percentage of vaccinations
delivered in rural and regional areas indicating that pro-
vision of pharmacist vaccination services facilitates access
to rural and remote consumers. Immuniser pharmacists
reported feeling confident in providing vaccination
services and were of the opinion that pharmacist vacci-
nation services should be expanded to other vaccina-
tions. Pharmacists also reported significant professional
satisfaction in providing the service. All participants
intended to continue providing influenza vaccinations in
2016.
Convenience and accessibility were important aspects
in usage of services and the majority of consumers lived
in the postcode where the pharmacy was located. Recent
Australian research reinforced convenience as the
leading factor influencing consumers’ choice of phar-
macy services.43 Convenience and accessibility were simi-
larly highlighted as important considerations in initial
US pharmacist vaccination service findings.9 These
results are also consistent to two recent Canadian studies
that indicated convenience was a main advantage to
being vaccinated at a pharmacy.17 44 Providing easy
access through appointment or walk-in vaccinations gave
consumers flexibility in accessing immunisation services.
International research has also shown that specific con-
sumer groups (ie, younger, working-aged, healthy
adults) prefer after-hours services45 when traditional vac-
cination providers are likely to be unavailable and hence
community pharmacy vaccination services could attract
these groups.
According to the Global Vaccine Action Plan 2011–2020,46
countries are encouraged to set national immunisation
targets and have strategies in place to meet these targets.
In some parts of Australia, specifically in WA, overall
immunisation rates are below the national immunisation
coverage target of 95% and are considered lower than in
other Australian jurisdictions.47 48 Some studies conducted
overseas have shown increased immunisation rates in the
community with the addition of pharmacists as immunisa-
tion providers through the provision of vaccination ser-
vices.44 49 However, a recent evaluation of London
vaccination data showed no evidence of increased influ-
enza vaccination uptake resulting for a pharmacy initiative
allowing the administration of influenza vaccinations in
pharmacies50 whereas the 2014 Canadian study showed
marginal increases.17 The ongoing evaluation of the
potential impact of changes to legislation to enable phar-
macists, and other health professionals such as nurse prac-
titioners to be able to administer vaccinations is therefore
important in informing policy.
As stated in the WA Immunisation Strategy 2013–
2015,48 “WA has the lowest GP-to-population ratio in the
nation. Optimising the use of nurses and other trained
health care workers is, therefore, critical to WA’s efforts
to expand and improve immunisation service delivery.”
With an increased number of trained immuniser pharma-
cists and a concerted advertising programme to raise
community awareness, pharmacists could contribute
towards meeting the goal and aims of this strategy, ultim-
ately achieving an improved immunisation rate.
The majority of exit survey participants commented that
pharmacist vaccinations should be expanded to people
<18 years old. A 2012 US study of 86 parents showed they
felt confident about a pharmacist providing influenza vac-
cinations to their children.51 The Australian Influenza
Surveillance Report highlighted that children <15 years
old accounted for one-third of all influenza notifications.52
Expanding the scope to include younger children there-
fore requires consideration as allowing pharmacists to
immunise children will assist with reducing the number of
influenza infections in this age group.
Availability of pharmacist vaccination services facili-
tated access to rural and remote consumers, similar to
findings from international studies.53–55 An area that
should be explored is provision of pharmacist vaccin-
ation services to specific deprived groups such as ATSI
people. An US study of pharmacist vaccination services
provided to deprived communities showed a significant
impact on increasing adult immunisation rates in these
communities.56 However, the requirement for two phar-
macists may limit service provision in these areas and
some interview participants commented that it was chal-
lenging to have two pharmacists on board in rural/
regional pharmacies. This requirement should be recon-
sidered by legislative authorities as such restrictions are
not required with such a low-risk procedure.
In addition to influenza vaccination, other vaccinations
the participants indicated that could be administered by
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pharmacists included pertussis, tetanus, measles, mumps
and rubella, hepatitis A and B, pneumococcal, typhoid
and travel vaccines in general. Various of these vaccina-
tions are already included as pharmacists’-administered
vaccinations in the USA,15 57–59 UK20 21 and NZ.24
Consideration should be given to broadening the types of
vaccinations available particularly of those vaccines that
have consistently low rates of community uptake such as
HPV,60 and in areas of low vaccination such as in ATSI
communities.61
Provision of pharmacist vaccination services created
opportunities to establish therapeutic relationships. This
facilitated holistic patient-centred care which fits the
Government’s approach towards funding for the provision
of professional services.62 Pharmacists are well placed to
ensure good communication between healthcare providers
and maintain good surveillance and immunisation registra-
tion quality. However, interview participants commented
that appropriate funding should be considered, a finding
that is similar to recently published US research that identi-
fied inconsistent reimbursement as a challenge for phar-
macists that need to be addressed.49 From the perspective
of healthcare resource allocation in Australia, pharmacist-
delivered vaccinations saves money for the government as
pharmacists are not paid a consultation fee through
Medicare, as is the case with other health professionals,
that is, GPs. However, for the service to be sustainable gov-
ernment funding to pharmacists needs to be considered.
Strengths and weaknesses
This is the first study that comprehensively evaluated the
implementation of pharmacist vaccination services in
Australia and explored the uptake of the services from
pharmacists’ perspectives. The study involved mixed
methodology with both quantitative and qualitative data
through surveys, pharmacy computer records and inter-
views. The various data sources enabled contextualising
and triangulation of information and hence enriched
the exploration of the research topic.63 However, this
study had limitations as the research involved voluntary
self-administered baseline and exit surveys to pharma-
cists who chose to provide pharmacist vaccination ser-
vices. These pharmacists potentially were biased in their
responses. The interview participants involved purposive
sampling of immuniser pharmacists who indicated their
willingness to be interviewed. Although there is a likeli-
hood of bias, it was considered important to interview
participants who had experience in the delivery of vac-
cination services. Also, this study was conducted in WA
and findings might differ in other Australian jurisdic-
tions due to slight differences in legislative provisions.
CONCLUSION
This initial evaluation of WA pharmacist vaccination ser-
vices showed that vaccine delivery was safe. Convenience
and accessibility were important aspects in service usage.
There is scope to expand pharmacist vaccination services
to other vaccines and younger children; however, gov-
ernment funding to pharmacists needs to be considered.
Greater numbers or immunisation rates could be
achieved with an increased number of trained pharma-
cists, appropriate funding and a concerted advertising
programme to raise community awareness.
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